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Summary 
Background and purpose: Strategies designed to enhance cerebral cAMP have been 
proposed as symptomatic treatments to counteract cognitive deficits. However, 
pharmacological therapies aimed at reducing type 4 phosphodiesterase (PDE4), the main class 
of cAMP catabolising enzymes in the brain, have produced severe emetic side-effects. We 
have recently synthesised a 3-cyclopentyloxy-4-methoxybenzaldehyde derivative, structurally 
related to rolipram, and endowed with selective PDE4D inhibitory activity. The aim of the 
present study was to investigate the effect of the new drug, namely GEBR-7b, on memory 
performance, nausea, hippocampal cAMP and amyloid-β (Aβ) levels. 
Experimental approach: To measure memory performance, we performed object 
recognition tests on rats and mice treated with GEBR-7b or rolipram. The emetic potential of 
the drug, again compared with rolipram, was evaluated in rats using the taste reactivity test 
and in mice using the xylazine/ketamine anaesthesia test. Extracellular hippocampal cAMP 
was evaluated by intracerebral microdialysis in freely-moving rats. Levels of soluble Aβ 
peptides were measured in hippocampal tissues and cultured N2a cells by ELISA. 
Key results: GEBR-7b increased hippocampal cAMP, did not influence Aβ levels and 
improved spatial, as well as object memory performance in the object recognition tests. The 
effect of GEBR-7b on memory was 3 to 10 times more potent than that of rolipram, and its 
effective doses had no effect on surrogate measures of emesis in rodents.  
Conclusion and implications: Our results demonstrate that GEBR-7b enhances memory 
functions at doses that do not cause emesis-like behaviour in rodents, thus offering a 
promising pharmacological perspective for the treatment of memory impairment.  
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Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; cAMP, cyclic adenosine 
monophosphate; CNS, central nervous system; CREB, cAMP response element-binding 
protein; DMSO, dimethylsulfoxide; LTP, long term potentiation; N2a, mouse Neuro-2a cells; 
OLT, object location test; ORT, object recognition test; PDE4, type 4 phosphodiesterase; 
PKA, protein kinase A  
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Introduction 
 
Cyclic adenosine monophosphate (cAMP) is a central component of signalling pathways 
regulating a wide range of biological functions, including the cognitive process of memory 
consolidation. Cerebral cAMP activates protein kinase A (PKA) and the subsequent 
downstream target cAMP response element-binding (CREB) protein, generating a signalling 
cascade that is important in the mediation of synaptic plasticity and memory (Bailey et al., 
1996; Frey et al., 1993). A large body of evidence has shown that long term potentiation 
(LTP), the neurochemical substrate of learning and memory processes, requires the 
functioning of the cAMP/PKA/CREB pathway and its genetic or pharmacological 
manipulation can affect cognitive functions (Barad et al., 1998; Bourtchouladze et al., 2003; 
Li et al., 2011). 
Cerebral levels of cAMP critically depend on the activity of type 4 phosphodiesterase 
(PDE4), a family of cAMP-catabolising enzymes. PDE4s are encoded by four independent 
genes (Pde4a to Pde4d), which can give rise to multiple spliced variants differently expressed 
in the central nervous system (CNS) (Cherry et al., 1999; Houslay et al., 2003; Perez-Torres 
et al., 2000). Their differential distribution in brain regions has suggested distinct roles of 
individual PDE4 subtypes in CNS functions. Among the different classes of PDE4 presently 
known, PDE4D is the subtype that is likely to influence memory processes. This is consistent 
with its predominant expression in hippocampal CA1 region (Perez-Torres et al., 2000) and 
with the important role played in hippocampal LTP (Rutten et al., 2008). Moreover, different 
lines of evidence, showing that pharmacologically induced overexpression of PDE4D impairs 
memory (Giorgi et al., 2004), and that its knocking-out exerts cognitive-enhancing effects and 
stimulates hippocampal neurogenesis (Li et al., 2011), have strongly supported the concept 
that selective PDE4D inhibition may be beneficial for the treatment of memory loss 
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characterising several CNS disorders (e.g. Alzeimer’s disease; AD). Indeed, it has been 
consistently demonstrated that PDE4 inhibitors, such as rolipram, can facilitate LTP and 
improve memory functions in a variety of cognitive tasks, both under physiological and 
pathological conditions (Reneerkens et al., 2009). In particular, rolipram has been found 
effective in reducing cognitive impairments in different transgenic AD models (Comery et al., 
2005; Costa et al., 2007; Gong et al., 2004), as well as in rats injected with amyloid-β (Aβ) 
peptides (Cheng et al., 2010). PDE4 inhibitors have been widely investigated also for their 
antidepressant effects in both animals and humans (Zhang, 2009) and, within this context, 
PDE4D has been proposed as the PDE subtype responsible for the antidepressant activity of 
rolipram (Zhang et al., 2002). However, despite its potential clinical relevance, therapeutic 
use of rolipram is limited because of the acute emesis occurring after its administration 
(Hebenstreit et al., 1989).  
Our studies, aimed at developing novel PDE4 inhibitors, led us to synthesise a series of 3-
cyclopentyloxy-4-methoxybenzaldehyde derivatives structurally related to rolipram and 
endowed with selective PDE4D inhibitory activity (Bruno et al., 2009).  
Here, to ascertain the potential clinical relevance of the new PDE4D inhibitors, we evaluated 
the effect of the most active and selective one, namely GEBR-7b, on the memory 
performance of rodents in the object recognition test (Ennaceur et al., 1988) and object 
location test, a spatial variant of the former (Rutten et al., 2009). Given the emetic properties 
of PDE4 inhibitors, we also analysed the ability of GEBR-7b to stimulate conditioned gaping 
in rats and to shorten α2 adrenergic receptor-mediated xylazine/ketamine anaesthesia in mice, 
two well established surrogate measures of emesis in rodents, which are nonvomiting species 
(Grill et al., 1978; Parker et al., 2006; Robichaud et al., 2002). In addition, using intracerebral 
microdialysis, we assessed the effect of the drug on the hippocampal levels of cAMP in freely 
moving rats. Finally, as it has been suggested that PDE4D inhibitors might be useful in AD 
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(Burgin et al., 2010; Li et al., 2011) and that Aβ could differentially modulate hippocampal-
dependent memory processes by positively or negatively influencing LTP (Haass et al., 2007; 
Puzzo et al., 2008), we have also evaluated the effect of GEBR-7b on Aβ levels both in vivo 
and in vitro. 
 
Methods 
 
Object location and recognition tests 
Twenty-four 3-month-old male Wistar rats (Charles River, The Netherlands) and twenty-four 
7-week-old male C57Bl6/6NCrl mice (Charles River, France) were used. In order to test the 
animals in their active phase, they were kept under a reversed 12/12-hour light/dark cycle. All 
animals were housed individually in standard Makrolon homecages and had free access to 
food and water. GEBR-7b was dissolved in dimethylsulfoxide (DMSO) and kept at 4 ºC; this 
stock solution was used for further dilutions in 0.5% methylcellulose. All injection solutions 
consisted of 0.5% methylcellulose with fixed DMSO percentages (0.01% for rats and 0.005% 
for mice). Based on previous findings, administration of PDE4 inhibitors was performed 3 h 
after the first trial, as this has an optimum effect on object memory performance (Rutten et 
al., 2007; 2009). Injection volumes were 1 ml/kg for rats (intraperitoneal; i.p.) and 8 ml/kg for 
mice (subcutaneous; s.c.). 
Object recognition testing (ORT) was performed as described elsewhere (Ennaceur et al., 
1988). The details on the apparatus and objects are identical to those described in previous 
studies with rats (Rutten et al., 2009) and mice (Sik et al., 2003). A testing session consisted 
of two trials. The duration of each trial was 3 min for rats and 4 min for mice. Only mice were 
placed in an empty cage for 4 min before the first trial (T1), in order to increase arousal at 
testing. During T1 the apparatus contained two identical objects. After the first exploration 
 6
period, the animal was put back in its home cage. Exploration was defined directing the nose 
to the object at a distance of not more than 2 cm and/or touching the object with the nose. 
After a 24 h delay interval, the animal was put in the apparatus for the second trial (T2). In T2 
of the object location test (OLT), two identical objects as in T1 were used; one object was 
placed in the previously used position, whereas the other was placed in a novel position. The 
novel position of the object could be either a fixed distance toward the front or a fixed 
distance toward the back of the arena for both objects (for details see Rutten et al., 2009; 
Vanmierlo et al., 2009). All mice and rats were tested in the OLT. In the ORT, one of the two 
familiar objects in T2 was replaced by a new object. Only rats were tested in the ORT. All 
objects and locations were used in a balanced manner to exclude possible object and/or 
location preferences. To avoid olfactory cues, the objects were thoroughly cleaned with 70% 
ethanol after each trial. Before testing the drugs, animals were handled daily and adapted to 
the procedures in two days, i.e. they were allowed to explore the apparatus twice for 3 min 
each day. All four objects used in this study were presented in these two subsequent days. 
Afterwards, animals were adapted to the treatment by one i.p. or s.c. saline injection for rats 
and mice, respectively. The testing order of conditions was determined randomly. A within-
design was used and all animals were treated once with each condition. T1 was always on 
Monday and Thursday in order to have a sufficient wash-out period between compound 
sessions. The experimenter was blind of the testing protocol. All experimental procedures 
were approved by the ethical committee of the Maastricht University and met the 
governmental guidelines on animal experiments. 
The time spent exploring the two identical objects in T1 was indicated as “a1” and “a2”, 
respectively. The time spent exploring the familiar and the new object or location in T2 was 
indicated as “a” and “b”, respectively. The following variables were calculated: e1 = a1 + a2; 
e2 = a + b and d2 = (b – a)/ e2. e1 and e2 are measures of the total exploration time of both 
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objects during T1 and T2, respectively. d2 is a relative measure of discrimination, corrected 
for exploration activity (e2). Animals with an e2 lower than 7.5 seconds were excluded. 
Comparisons within a treatment condition were based on a special paired t-test, i.e. the one-
sample t-test, which evaluates the significance of d2 for a given session by comparing its 
mean value with zero. Statistical significance between treatment conditions was calculated 
using a one-way ANOVA followed by Bonferroni post-hoc comparison test. 
 
Taste reactivity test 
Twenty-three male (2- to 3-month-old) Sprague-Dawley rats were single-housed at an 
ambient temperature of 21°C, with a reversed 12/12-hour light/dark cycle and free access to 
food and water. Surgical procedure is reported in detail elsewhere (Rock et al., 2009). Briefly, 
all rats were implanted with intra-oral cannulae inserted at the base of the neck, directed 
around the ear and brought out behind the first molar inside the mouth. For three days 
following surgery, rats were monitored and had their cannulae flushed daily with 
chlorhexidine. The taste reactivity test (Grill et al., 1978) room was dark with two 50-Watt 
white lights on either side of the conditioning chamber, which was made of clear Plexiglass 
sides (22.5 x 26 x 20 cm) with a clear lid. A mirror beneath the chamber on a 45° angle 
facilitated viewing of the ventral surface of the rat. A video camera (Sony DCR-HC48) with 
fire-wire feed to a computer was used to record the orofacial and somatic reactions of the rat 
during conditioning and testing. Three days after recovering from surgery, the rats received an 
adaptation trial in which they were placed in the chamber with their cannula attached to an 
infusion pump (Harvard Apparatus) for fluid delivery. Water was infused into their intra-oral 
cannulae for 5 min at the rate of 1 ml/min and rats were then returned to their home cage. The 
animals received the first conditioning trial 24 h after the adaptation trial. There were a total 
of three conditioning trials, with 72-96 h between each trial. On each conditioning trial, rats 
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were individually placed in the chamber and were intra-orally infused with 17% sucrose 
solution for 5 min at a rate of 1 ml/min while the orofacial responses were video-recorded. 
Immediately following the sucrose infusion, the rats were injected with: vehicle (n = 5), 0.003 
mg/kg GEBR-7b (n = 6), 0.3 mg/kg GEBR-7b (n = 5), 0.3 mg/kg rolipram (n = 7). All drugs 
were dissolved in DMSO, diluted in 0.5% methylcellulose and administered intraperitoneally. 
The control group received the same concentration of DMSO administered to the highest 
GEBR-7b dose group (maximally 0.005% DMSO). The fourth trial proceeded just as a 
conditioning trial, except that no injection was delivered afterwards. The videotapes were 
later scored by an observer blind to the experimental conditions using “The Observer” 
(Noldus, USA) for the behaviours of gaping (large openings of the mouth and jaw, with lower 
incisors exposed). Statistical significance between treatment conditions was calculated using a 
one-way ANOVA followed by Bonferroni post hoc comparison test. All procedures adhered 
to the guidelines of the Canadian Council of Animal Care and were approved by the Animal 
Care Committee of University of Guelph. 
 
Xylazine/ketamine induced α2-adrenergic receptor-mediated anaesthesia test 
Seven-week-old male C57Bl6/6NCrl mice were anaesthetised with an i.p. injection consisting 
of 60 mg/kg ketamine (Eurovet Animal Health, The Netherlands) and 10 mg/kg xylazine 
(CEVA Santé Animale, The Netherlands). Fifteen minutes after induction of anaesthesia, 7-8 
animals per group were treated with rolipram (0.03 and 0.1 mg/kg s.c.), GEBR-7b (0.003, 
0.03, 0.1 and 0.3 mg/kg s.c.), or vehicle (0.07% DMSO in 0.5% methylcellulose) and placed 
in dorsal position. The time delay to the recovery of the righting reflex was used as an 
endpoint to measure the duration of anaesthesia. Animals recovering from anaesthesia before 
the treatment injection were excluded from analysis. Statistical significance between 
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treatment conditions was calculated using a one-way ANOVA followed by Bonferroni post-
hoc comparison test. 
 
Microdialysis surgery and experiments 
Detailed description of the surgical procedure is reported elsewhere (Fedele et al., 1997). 
Briefly, male Sprague-Dawley rats (2- to 3-month-old; Charles River, Italy) were 
anaesthetised with chloral hydrate (400 mg/kg), placed in a stereotaxic frame (David Kopf 
Instruments, USA) and implanted with microdialysis probes which were transversely 
positioned (horizontal microdialysis) into the dorsal hippocampi according to the following 
coordinates: AP = +3.8, H = +6.5 from the interaural line (Paxinos & Watson, 1986). A piece 
of dialysis fibre made of a co-polymer of acrylonitrile sodium methallyl sulphonate (AN69HF 
Hospal S.p.A., Italy; 0.3 mm outer diameter, 40 kDa mol. wt. cut-off) was covered with 
epoxy glue to confine dialysis to the area of interest (8 mm glue-free length). The skull was 
exposed and two holes were drilled on the lateral surfaces; the dialysis probe, held straight by 
a tungsten wire inside, was inserted transversely into the brain so that the glue-free zone was 
exactly located into the target area. The tungsten wire was withdrawn and stainless steel 
cannulae (22-gauge diameter, 15-mm long) were glued to the ends of the fibre bent up and 
fixed vertically to the skull with dental cement and modified Eppendorf tips. Rats were 
allowed to recover in their home cages for 24 h. The day after surgery, rats were placed into 
observation cages and the probes infused at a flow rate of 5 µl/min (CMA/100 microinjection 
pump, CMA Microdialysis, Sweden) with modified Ringer’s medium containing (in mM): 
NaCl 145, KCl 3, MgCl2 1, CaCl2 1.26, buffered at pH 7.4 with 2 mM phosphate buffer. 
Following a stabilisation period of 1 h, consecutive samples were collected every 20 min; 
GEBR-7b or rolipram were locally administered at different concentrations through the 
dialysis probe (retrodialysis) after three control samples had been collected to estimate cAMP 
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basal values and were present in the infusion solution for the time reported in the figures. 
GEBR-7b and rolipram were dissolved in DMSO at the concentration of 3 or 10 mM and 
diluted down to the desired concentration in modified Ringer’s medium. 1% DMSO was also 
present in the infusion solution for 120 min before drug administration. Under our 
experimental conditions, the in vitro recovery for cAMP amounted to 12.35 ± 0.11% (mean ± 
SD, n = 3 different probes). At the end of the experiment, rats were sacrificed and the correct 
position of the probe was verified by optical examination of the fibre tract. Animals 
presenting hemorrhagic lesions were rejected. cAMP content in the dialysates was assayed 
with a commercially available radioimmunoassay kit (IZOTOP, Institute of Isotopes Co., 
Hungary) using the acetylation protocol (standard curve range 2-128 fmol/100 μl) and a 
modified bound/unbound separation protocol (Wang et al., 2004b). The data presented (mean 
± S.E.M) are expressed as percentages of the mean basal value (defined as 100%), which was 
determined by averaging the content of the first 3 samples collected before drug treatments. 
Differences were analysed by two-way ANOVA for repeated measures followed by 
Bonferroni post-hoc comparison test. Experimental procedures were carried out in accordance 
with the European legislation on the use and care of laboratory animals (CEE 86/609). 
 
Cell culture and treatments 
The cells used in this study (mouse Neuro-2a, N2a, stably expressing wild type human APP 
695) were obtained from Peter Davies (Albert Einstein College of Medicine, Bronx, NY) and 
grown in 50% DMEM, 50% OptiMEM, with 0.1 mM non-essential amino acids, 200 µg/ml 
geneticin and 5% fetal bovine serum. Treatments started 16-18 h after plating the cells onto 6-
well plates (300,000 cells/well). Serial dilutions of 10 mM GEBR-7b stock in DMSO were 
used in order to add 1 μl/ml DMSO to each well. Twenty-four hours after the treatment, 
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conditioned media were collected, centrifuged at 1000 x g for 10 min to remove cell debris, 
and stored at -80°C for later assessments.  
 
Preparation of hippocampal homogenates 
Male Sprague-Dawley rats (2- to 3-month-old) were injected with: 0.003 mg/kg (n = 6) or 1 
mg/kg GEBR-7b (n = 6). Controls for each dosage (n = 6) received the corresponding volume 
of DMSO. All drugs were prepared in 0.5% methylcellulose vehicle and i.p. administered 
(injection volume 1 ml/kg). Three rats per group were sacrificed by decapitation either 6 or 18 
h after the treatment. The hippocampi were immediately extracted, flash frozen in liquid 
nitrogen and stored at -80°C. On assay days, frozen tissue samples were weighed and 
homogenised in ice-cold buffer containing 1% Complete protease inhibitor (Roche S.p.A., 
Italy), 50 mM Tris HCl (pH 7.6), 150 mM NaCl, 5 mM EDTA, at a ratio of 100 mg tissue/0.5 
ml buffer. The homogenates were centrifuged at 28,000 x g for 30 min. (4°C), and the 
supernatant was stored at -80°C until analysed. 
 
Aβ ELISA 
Conditioned media and hippocampal homogenates were analysed for soluble Aβx-40 and Aβx-
42 by sandwich ELISA (Wako Chemicals GmbH, Germany) according to manufacturer 
protocols. Statistical analysis was performed with a two-tailed Student's t test. 
 
Results 
 
Spatial and object recognition memory 
To determine whether the new rolipram-related compound GEBR-7b (Figure 1) affects the 
cognitive process of memory in rats and mice, we used the object location and the object 
 12
recognition tests, which are based on the natural tendency of rodents to explore unfamiliar or 
displaced objects (Ennaceur et al., 1988; Rutten et al., 2009). 
Total exploration times of the treatments with GEBR-7b or rolipram were not different from 
the vehicle treatments in all spatial and object memory tests (data not shown). In the spatial 
location test for rats, one-sample t-tests revealed that d2 values after 0.01 and 0.03 mg/kg 
rolipram treatments significantly differed from zero, indicating that the rats discriminated 
between locations at these doses. d2 values after rolipram treatment were found to be different 
from each other (F(3,89) = 3.34, P < 0.05). Post-hoc analysis revealed that the d2 value after 
0.03 mg/kg rolipram treatment was significantly higher than that of the vehicle condition, 
indicating a full spatial memory enhancement (Figure 2). One-sample t-tests revealed that the 
d2 values after all GEBR-7b treatments differed from zero. The d2 values differed between 
GEBR-7b treatments (F(4,114) = 3.12, P < 0.05). Post-hoc analysis revealed that the d2 value 
after 0.003 mg/kg GEBR-7b treatment was higher than after vehicle treatment (Figure 2). 
Thus, GEBR-7b completely improved spatial memory at 0.003 mg/kg. 
Spatial memory of mice was assessed to verify the effects of GEBR-7b on memory in a 
different animal species. In the object location task, paired t-tests revealed that the d2 value 
after 0.03 mg/kg rolipram treatment differed from zero. There were differences in d2 values 
between rolipram treatments (F(3,64) = 7.698, P < 0.001). Post-hoc analysis indicated that the 
d2 value after 0.03 mg/kg rolipram treatment was higher than after the vehicle administration 
(Figure 3). One-sample t-tests revealed that d2 values after 0.001 and 0.003 mg/kg GEBR-7b 
treatments differed from zero. Differences between d2 values after GEBR-7b treatment were 
present (F(4,79) = 5.898, P < 0.001). Post-hoc analysis indicated that the d2 value after 0.003 
mg/kg GEBR-7b injection was higher than after vehicle treatment (Figure 3).  
In the object recognition test in rats, one-sample t-tests indicated that the d2 value after 0.01 
mg/kg rolipram treatment differed from zero. Differences in d2 values between rolipram 
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treatments were found (F(3,85) = 6.123, P < 0.001). Post-hoc analysis revealed that the d2 
value after 0.01 mg/kg rolipram treatment was higher than after vehicle treatment, thus 
showing complete object memory enhancement (Figure 4). One-sample t-tests showed that d2 
values after 0.003 mg/kg GEBR-7b treatment differed from zero. There were differences 
between the d2 values of the GEBR-7b treatment conditions (F(3,78) = 4.724, P < 0.01). Post-
hoc analysis revealed that the d2 value in the 0.003 mg/kg GEBR-7b condition was higher 
than in the vehicle condition (Figure 4).  
 
Conditioned gaping in the taste reactivity test 
Because nausea and vomiting are common side-effects of PDE4 inhibitors (Hirose et al., 
2007; Robichaud et al., 2001; Zeller et al., 1984), we used the taste reactivity test (Grill et al., 
1978) to evaluate the emetic potential of GEBR-7b in rats. Although rodents are unable to 
vomit, they display characteristic gaping reactions when exposed to flavoured solutions 
previously paired with nausea-inducing agents; therefore, conditioned gaping in rats has been 
introduced as a selective index of nausea (Parker et al., 2006; Rock et al., 2009). Figure 5 
shows the mean number of gapes elicited during the 5 min intra-oral infusion of 17% sucrose 
solution paired with GEBR-7b or rolipram across trials. Statistical data analysis revealed a 
significant group effect only on trial 4 (F (3,19) = 8.6; P < 0.01). Bonferroni post-hoc 
comparison test indicated that 0.3 mg/kg rolipram stimulates a conditioned gaping response, 
following 3 conditioning trials, significantly greater than that elicited by vehicle, 0.003 or 0.3 
mg/kg GEBR-7b (P < 0.01), with no other significant effects.  
 
Recovery after xylazine/ketamine induced α2-adrenergic receptor-mediated anaesthesia  
PDE4 inhibitors mimic the pharmacological actions of α2-adrenoceptor antagonists. This has 
been postulated as the mechanism by which PDE4D inhibitors induce emesis. Since α2-
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adrenoceptor antagonists are also known to reverse xylazine/ketamine-induced anaesthesia, 
we used this latter effect as a surrogate measure of emesis in mice (Robichaud et al., 2002). 
As expected, rolipram treatments significantly affected the duration of xylazine/ketamine-
induced anaesthesia (F(2,18) = 14.53, P < 0.001) (Figure 6). Post-hoc analysis indicated that 
the duration of xylazine/ketamine-induced anaesthesia was reduced, compared to vehicle, 
upon injection of the dose of rolipram effective in the memory tasks (0.03 mg/kg). GEBR-7b 
appeared to affect the recovery time (F(4,31) = 2.84, P < 0.05), but post hoc analysis revealed 
that this was not the case after the injection of 0.003, 0.03 and 0.1 mg/kg. Only a dose (0.3 
mg/kg) 100 times higher than that effective in the memory tasks reduced the recovery time 
(Figure 6). 
 
Hippocampal levels of cAMP in freely moving rats 
To evaluate in vivo the effects of PDE4D inhibition on the hippocampal levels of cAMP, we 
performed intracerebral microdialysis experiments in freely-moving rats. Local administration 
of GEBR-7b by retrodialysis caused a concentration-dependent (30-100 μM) increase of 
extracellular cAMP. ANOVA analysis revealed that both time (F(8,64) = 4.19, P < 0.001) and 
concentrations (F(1,64) = 6.77, P < 0.05) had significant effects and that there was a 
significant interaction (F(8,64) = 2.13, P < 0.05). Post-hoc test indicated that, although at 30 
µM the drug slightly augmented extracellular cAMP (max. increase 20%), the effect did not 
reach statistical relevance; on the other hand, when GEBR-7b was infused at the 
concentration of 100 µM, a significant and constant 40-50% increase was observed (Figure 
7). Infusion of rolipram (30-100 μM) also resulted in the increase of extracellular cAMP, but 
the effect was more pronounced. ANOVA analysis revealed that both time (F(8,48) = 43.33, P 
< 0.0001) and concentrations (F(1,48) = 287.37, P < 0.0001) had significant effects and that 
there was a significant interaction (F(8,48) = 13.17, P < 0.0001). Post-hoc test indicated that 
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both rolipram concentrations elicited significant effects. In fact, a 50-60% elevation of 
extracellular cAMP was already evident at the concentration of 30 µM, whereas infusion of 
100 µM rolipram resulted in a 150-200% increase over basal levels (Figure 7).  
 
Aβ levels in hippocampal tissues and neuronal cultured cells 
Since it has been reported that picomolar concentrations of Aβ peptides may enhance synaptic 
plasticity (Puzzo et al., 2008), whereas higher concentrations inhibit hippocampal LTP and 
impair memory (Haass et al., 2007; Puzzo et al., 2008), it was of interest to investigate 
whether the selective PDE4D inhibitor could influence the hippocampal content of Aβ 
peptides. To this purpose, rats were i.p. injected with vehicle, 0.003 or 0.1 mg/kg GEBR-7b 
and sacrificed 6 or 18 h after the treatment. Hippocampal levels of soluble Aβ40 and Aβ42 
were measured by specific sandwich ELISA and normalised to total protein concentration in 
each sample. The results shown in Figure 8A indicate that, at least under the tested conditions, 
neither the low nor the high dose of GEBR-7b significantly affected the hippocampal content 
of Aβ peptides. To further investigate this issue, we tested the ability of GEBR-7b to 
modulate the secretion of Aβ40 and Aβ42 in a mouse neuronal cell line (N2a) stably 
transfected to express the human amyloid precursor protein (APP). Assuming a 150 ml of 
body fluids for a rat weighing 250 g, a complete absorption of the drug, no metabolic 
degradation or excretion and a homogeneous distribution throughout the body, the i.p. 
injection of 0.003 and 0.1 mg/kg GEBR-7b would lead to a concentration of ~ 0.013 and 0.43 
μM, respectively (Fedele et al., 1998). Thus, we exposed N2a cells to 0.01, 0.1, and 1 μM 
GEBR-7b for 24 h and performed Aβ-specific sandwich ELISA on the conditioned culture 
media. Consistent with the results obtained in hippocampal tissues, statistical analysis 
revealed that, compared to the controls, GEBR-7b did not change the amount of Aβ40 and 
Aβ42 secreted by the cells in the extracellular medium (Figure 8B).  
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Discussion and conclusions 
 
The data presented here show that the new selective PDE4D inhibitor GEBR-7b is able to 
improve late phase consolidation processes of spatial and object recognition memory and to 
increase the hippocampal levels of cAMP in vivo. cAMP is known to play a key role in 
regulating the complex mechanisms of cognitive processes. In fact, it has been reported that 
hippocampal LTP can be blocked by PKA inhibitors whereas pharmacological activation of 
adenylyl cyclase (AC) results in the induction of long-lasting synaptic potentiation that 
occludes tetanus-induced LTP (Huang et al., 1994; Nguyen et al., 1994). Accordingly, AC1 
and AC8 double knock-out mice do not express LTP and exhibit significant memory deficits 
(Wong et al., 1999) whilst overexpression of AC1 results in enhanced LTP and recognition 
memory (Wang et al., 2004a). A large body of evidence has also convincingly demonstrated 
that blocking cAMP degradation improves memory functions in unimpaired rodents (i.e. 
attenuates natural forgetting) and ameliorates cognitive alterations in a variety of 
pharmacologically-induced and transgenic-based memory deficit models, including murine 
models of AD (Reneerkens et al., 2009; Zhang et al. 2000; Bourtchouladze et al. 2003). 
GEBR-7b shows selective PDE4D inhibitory properties, it being almost inactive toward 
PDE4A4, PDE4B2 and PDE4C2 isoforms (Bruno et al., 2009), and is effective in two 
different cognitive tasks and in two different animal species. Thus, our behavioural results 
provide further evidence that PDE4D plays a critical role in the mediation of memory 
processes (Burgin et al., 2010; Li et al., 2011; Zhang et al., 2005). 
Collectively, the behavioural effects shown by GEBR-7b indicate that the optimum dose to 
improve spatial and object memory consolidation processes is approximately 0.003 mg/kg. 
While lower doses are not effective enough, higher doses show a decrease in efficacy, most 
likely due to the accumulation of side-effects. In view of the potential use of PDE4D 
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inhibitors in AD (Burgin et al., 2010; Li et al., 2011) and based on the evidence that Aβ 
inhibits hippocampal LTP at high concentrations and improves synaptic plasticity and 
memory when applied in lower amounts (Haass et al., 2007; Puzzo et al., 2008), it was of 
interest to investigate whether GEBR-7b could affect the production of Aβ peptides. In this 
context, however, our in vivo and in vitro results suggest that the lack of memory-enhancing 
effects, seen at high doses of GEBR-7b, as well as the efficacy of the lower doses, may not be 
related to the production of Aβ. This is also consistent with the observation that chronic 
rolipram treatment did not affect cerebral levels of Aβ40 and Aβ42 in a mouse model of AD 
(Gong et al., 2004). 
Despite the beneficial effects of PDE4 inhibitors, such as rolipram, on memory functions, one 
major problem for their clinical application concerns the emetic side-effect that occurs after 
acute administration. Within this context, it is worth noting that the effects on memory 
consolidation of GEBR-7b in rats and mice were observed at doses between 3 and 10 times 
lower than that of rolipram. These findings, together with the notion that GEBR-7b exerts a 
more isoform-specific activity, compared to rolipram, led us to hypothesise a reduced emetic 
effect. As a matter of fact, using GEBR-7b in the taste reactivity test, we did not observe 
emesis-like behaviour in rats, even at doses up to 100 times higher than those effective in the 
object recognition and location tasks. Using the xylazine/ketamine test, this lack of emetic 
effect was also observed in mice at doses 30 times higher than those improving behavioural 
performances in the object location test; GEBR-7b induced an emetic-like response only 
when administered at a 100 times higher dose. However, PDE4D seems the predominant 
PDE4 subtype in emesis-associated brain regions such as the area postrema and the nucleus of 
the solitary tract (Cherry & Davis, 1999; Lamontagne et al., 2001; Mori et al., 2010). In 
addition, both PDE4 and PDE4D selective inhibitors (i.e. rolipram, D157140, D159382) have 
been shown to cause emetic-like behaviour in the xylazine/ketamine test in mice already at 
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doses which are effective in the object recognition test (Burgin et al., 2010). It is therefore 
likely that the greatly reduced emetic effect shown by GEBR-7b in the present study is due to 
the relative low doses required to improve memory. 
As PDE4s are involved in the degradation of the second messenger cAMP, which seems to 
play a critical role in cognitive processes, we also evaluated whether GEBR-7b could 
influence, in vivo, the hippocampal levels of cAMP. Indeed, results obtained by intracerebral 
microdialysis show that GEBR-7b causes a significant 40% increase of extracellular cAMP in 
the hippocampus of freely moving rats. It could be argued that the concentrations of GEBR-
7b used in the microdialysis experiments (30 and 100 µM) are not comparable to the doses 
found effective in the cognitive tests (0.001-0.003 mg/kg). However, since microdialysis 
measures cAMP in the extracellular milieu and not directly in the intracellular compartment, 
where it is supposed to influence physiological functions (e.g. cognition), it is difficult to 
establish a direct correlation between the doses effective in behavioural tests and 
microdialysis experiments. Cyclic nucleotides (both cAMP and cGMP) are extruded from 
cells into the extracellular milieu by low-affinity, active transport systems (MRP4/5), and 
represent only a small fraction of the intracellular counterpart (Wielinga et al., 2003). 
Therefore, it is likely that in order to get an intracellular cAMP elevation able to be 
significantly reflected in the extracellular space, we need a much stronger PDE4 inhibition 
than that necessary to improve cognition in the behavioural tasks. Consistent with this,  
rolipram elicited a significant response already at 30 µM, and elevated extracellular cAMP by 
approx. 160% at 100 µM. Thus, although not directly correlating with the behavioural data, 
our microdialysis results represent the “proof of concept” that GEBR-7b does increase in vivo 
the hippocampal levels of cAMP. Moreover, the evidence that GEBR-7b has a markedly 
lower influence on extracellular cAMP, compared to rolipram, is consistent with its selectivity 
towards PDE4D. 
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In conclusion, our data show that GEBR-7b increases hippocampal cAMP and is able to 
enhance memory functions at doses that do not cause emesis-like behaviour in rodents. These 
findings provide further support to the idea that targeting PDE4D with selective inhibitors 
may represent an innovative cognitive-enhancing pharmacological strategy.  
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Figure legends 
 
Figure 1 Chemical structure of GEBR-7b. 
 
Figure 2 Influence of rolipram and GEBR-7b on the discrimination index (d2) in the 
object location test in rats (means ± S.E.M.). A difference from the vehicle condition is 
depicted with asterisks (Bonferroni comparison t-test: *P < 0.05 ). A difference from zero is 
depicted with hashes (one-sample t-tests: #P < 0.05, ##P < 0.01, ###P < 0.001). n = 22-24. 
 
Figure 3 Influence of rolipram and GEBR-7b on the discrimination index (d2) in the 
object location in mice (means ± S.E.M.). A difference from the vehicle condition is depicted 
with asterisks Bonferroni comparison t-test: *P < 0.05, **P < 0.01). A difference from zero is 
depicted with hashes (one-sample t-tests: #P < 0.05, ##P < 0.01, ###P < 0.001). n = 14-16, 
except for the vehicle group, where n = 23. 
 
Figure 4 Influence of rolipram and GEBR-7b on the discrimination index (d2) in the 
object recognition test in rats (means ± S.E.M.). A difference from the vehicle condition is 
depicted with asterisks (Bonferroni comparison t-test: *P < 0.05, **P < 0.01). A difference 
from zero is depicted with hashes (one-sample t-tests: ###P < 0.001). n = 21-23. 
 
Figure 5 Influence of rolipram and GEBR-7b on conditioned gaping in rats. Graph 
presents mean number (± S.E.M.) of gapes elicited by the 5 min intra-oral infusion of 17% 
sucrose solution paired with the various conditioning drugs across 3 conditioning trials (trials 
1-3) and the test trial (trial 4). Vehicle (n = 5), 0.003 mg/kg GEBR-7b (n = 6), 0.3 mg/kg 
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GEBR-7b (n = 5), 0.3 mg/kg rolipram (n = 7). Bonferroni post-hoc comparison test: **P < 
0.01 vs the other conditions tested in trial 4. 
 
Figure 6 Influence of rolipram and GEBR-7b on the recovery time after 
xylazine/ketamine induced α2-adrenergic receptor-mediated anaesthesia in mice (means ± 
S.E.M). A difference from the vehicle condition is depicted with asterisks (Bonferroni 
comparison t-test: *P < 0.05, ***P < 0.001; n=5-7/group).  
 
Figure 7 Effects of rolipram and GEBR-7b on cAMP extracellular levels in hippocampi 
of freely moving rats. Rolipram or GEBR-7b were infused through the dialysis probe after 
three consecutive basal samples had been collected and for the time indicated by the 
horizontal empty bar. Graphed data represent means ± S.E.M. of four (rolipram) or five 
(GEBR-7b) independent experiments (Bonferroni comparison test: *P < 0.05, **P < 0.01 and 
***P < 0.001 vs basal level). 
 
Figure 8 Effect of GEBR-7b on Aβ levels in vivo and in vitro. (A) Effect of GEBR-7b 
on the hippocampal content of Aβ40 and Aβ42. Rats have been injected i.p. with the indicated 
doses of drug or vehicle and sacrificed either 6 or 18 h after the treatment. Hippocampal 
homogenates were subjected to soluble Aβ40 and Aβ42 specific ELISA. Data, calculated as 
pmol/g protein, are expressed as a percentage (means ± S.D; n = 3) of the corresponding 
control group. (B) Effect of GEBR-7b on the secretion of Aβ40 and Aβ42 in neuronal cultured 
cells. Conditioned media from N2a cells treated for 24 h with GEBR-7b or DMSO were 
subjected to specific Aβ ELISA. Results are expressed as means ± S.D. for four independent 
experiments. Statistically significant differences were not detected either in (A) or in (B) (P > 
0.05 vs the corresponding control group). 









